Remove ads
Pharmaceutical drug From Wikipedia, the free encyclopedia
Denileukin diftitox, sold under the brand name Ontak among others, is an anti-cancer medication used for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.[3]
Clinical data | |
---|---|
Trade names | Ontak, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611024 |
License data | |
Routes of administration | Intravenous |
Drug class | Antineoplastic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 70-80 min |
Identifiers | |
| |
CAS Number | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C2560H4042N678O799S17 |
Molar mass | 57647.46 g·mol−1 |
(what is this?) (verify) |
Denileukin diftitox is indicated for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.[1][2]
The prescription label contains a boxed warning that capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.[1][2]
In 1999, denileukin diftitox was approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma.[1][4]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.